K. H. Mok

Ken Hun Mok is currently Associate Professor in Biochemistry (Trinity College Dublin) and a member of the EUREKA IEP (Independent Evaluation Panel). His area of interest is in protein folding / misfolding, biomolecular NMR spectroscopy and NMR metabolomics, and has published in journals including Nature, Nature Communications, Nature Immunology, PNAS, and JACS), the inventor of more than 10 registered patents, and recently authored a book, "Letters from Dublin" (2023). Prof Mok’s expertise in using NMR spectroscopy to elucidate structurally-fluid protein-fatty acid complexes has led to the development of ‘Alpha1’ by start-up company HAMLET Pharma, which has concluded successful Phase I/II studies as a bladder cancer therapeutic (Brisuda A et al, Nature Commun 2021). In addition, he is serving as the technical consultant to two start-up companies, Meta-Flux Ltd (Ireland) and Lmntic Biotech (Korea).